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Background: Familial Hypocalciuric Hypercalcemia (FHH) is a generally benign disorder caused by heterozygous
inactivating mutations in the Calcium-Sensing Receptor (CaSR) gene resulting in altered calcium metabolism.
Objective: We report a case of unusually severe neonatal FHH due to a novel CaSR gene mutation that presented
with perinatal fractures and moderate hypercalcemia.
Case overview: A female infant was admitted at 2 weeks of age for suspected non-accidental trauma (NAT).
Laboratory testing revealed hypercalcemia (3.08 mmol/L), elevated iPTH (20.4 pmol/L) and low urinary calcium
clearance (0.0004). Radiographs demonstrated multiple healing metaphyseal and rib fractures and bilateral femoral
bowing. The femoral deformity and stage of healing were consistent with prenatal injuries rather than non-
accidental trauma (NAT). Treatment was initiated with cholecalciferol, 400 IU/day, and by 6 weeks of age, iPTH
levels had decreased into the high-normal range. Follow up radiographs demonstrated marked improvement of
bone lesions by 3 months. A CaSR gene mutation study showed heterozygosity for a T>C nucleotide substitution
at c.1664 in exon 6, resulting in amino acid change I555T in the extracellular domain consistent with a missense
mutation. Her mother does not carry the mutation and the father is unknown. At 18 months of age, the child
continues to have relative hyperparathyroidism and moderate hypercalcemia but is otherwise normal.
Conclusion: This neonate with intrauterine fractures and demineralization, moderate hypercalcemia and
hyperparathyroidism was found to have a novel inactivating missense mutation of the CaSR not detected in her
mother. Resolution of bone lesions and reduction of hyperparathyroidism was likely attributable to the natural
evolution of the disorder in infancy as well as the mitigating effect of cholecalciferol treatment.
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Familial hypocalciuric hypercalcemia (FHH) is an auto-
somal dominant disorder characterized by modestly ele-
vated serum calcium (Ca), inappropriately high
parathyroid hormone (PTH) levels and low urinary Ca
excretion [1]. FHH is caused by inactivating mutations
of the gene encoding the Calcium-Sensing Receptor
(CaSR), a seven transmembrane G-protein-coupled re-
ceptor. The CaSR is expressed primarily in parathyroid
chief cells and renal tubular cells and activates an* Correspondence: Ksenia.Tonyushkina@bhs.org
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distribution, and reproduction in any mediumintracellular signaling cascade to maintain serum cal-
cium levels within a narrow range. The gene for the
CaSR is located on chromosome 3q13.3–21 and encodes
for a 1078 amino acid sequence. Normally, elevated
levels of serum calcium activate the CaSR which then
inhibits both the secretion of PTH in the parathyroid
glands and the reabsorption of Ca2+ and Mg2+ in the
renal tubules. Therefore an inactivating mutation of the
CaSR leads to an elevated set point for serum Ca with
the consequence of having both inappropriate secretion
of PTH and renal reabsorption of Ca2+ [2].
The clinical impact of these mutations, at least 250 of
which have been reported, is highly variable and ranges
from totally asymptomatic to fatal. In the neonatalntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Tonyushkina et al. International Journal of Pediatric Endocrinology 2012, 2012:13 Page 2 of 7
http://www.ijpeonline.com/content/2012/1/13period, homozygous inactivating mutations result in
neonatal severe hyperparathyroidism (NSHPT) with se-
vere symptomatic hypercalcemia, undermineralized
bones, rib cage deformity, and long-bone and rib frac-
tures [3]. This condition requires aggressive medical
management often including emergent parathyroidect-
omy and can be fatal. Neonatal heterozygous inactivating
mutations are usually associated with modest hypercal-
cemia and hyperparathyroidism with mild or absent
bone disease which gradually evolves to a more benign
FHH phenotype [4-7]. Lastly, heterozygous FHH can go
wholly unrecognized for years until elevated serum cal-
cium is noted [8].
Herein, we present the case of a newborn girl with a
novel heterozygous inactivating mutation of the CaSR
gene, severe hyperparathyroidism, overt skeletal
demineralization, and perinatal fractures who was trea-
ted with cholecalciferol to moderate her clinical course.
Case presentation
A full term, healthy infant girl born via a normal spon-
taneous vaginal delivery presented at 2 weeks of age in a
Massachusetts emergency room for evaluation of
increased irritability and mild cough. Chest x-ray
showed a healing left proximal humeral metaphyseal
fracture and bilateral healing ribs fractures (Figure 1)
prompting admission for suspicion of NAT.
Physical exam
She was an alert, well-nourished African-American in-
fant girl whose length was at the 80th percentile, weight
was at the 75th percentile and head circumference was at
the 75th percentile for age. Exam findings were signifi-
cant for a prominent forehead and slightly bowed lowerFigure 1 Chest radiograph at presentation. There is
fragmentation, mixed sclerosis and lucency of the left upper
humeral metaphysis and a small amount of subperiosteal new bone
formation extending downward along the medial shaft (white
arrows). There are expanded healing rib fractures above both CP
angles (black arrows).extremities. There was full range of motion of extrem-
ities without pain.
Labs
A markedly elevated intact PTH with mild hypercalce-
mia and hypermagnesemia were noted on presentation
(Table 1). A spot urinary calcium to creatinine clearance
ratio was low[9]. After 2 days of hydration with normal
saline and low-calcium infant formula (calcium content:
<10 mg calcium/100 kCal, Vitamin D 0 IU/oz), serum
Ca levels decreased to the high normal range for age
(2.8 mmol/L ) (Figure 2).
Skeletal survey
Bone mineralization was subjectively diminished and
there was coarsening of trabecular markings. Repeat
CXR with oblique views confirmed multiple healing rib
fractures (Figure 1). There was callus formation, flaring,
medial beaking and fragmentation of both proximal hu-
meri, the left proximal femur and both distal femurs
(Figure 3). There was moderate antero-lateral bowing of
both proximal femoral shafts and posterior bowing of
the distal femoral shafts with thick confluent subperios-
teal new bone formation suggesting advanced stages of
healing/remodeling. The femoral bowing deformities
and advanced stages of remodeling were consistent with
prenatal changes, excluding NAT as a diagnostic consid-
eration. The differential diagnosis included osteogenesis
imperfecta and metabolic bone disease.
Hospital course
The elevated iPTH of 20.4 pmol/L with serum calcium
of 2.8 - 3.1 mmol/L led to suspicion of a CaSR mutation.
A Sestamibi Tc 99 scan was normal without evidence of
adenoma. Lab evaluation of the maternal calcium me-
tabolism was unrevealing (Table 1) and there was no
known metabolic bone disease on the maternal side. The
infant’s father was unknown. Regular formula was
restarted (calcium content 67 mg/100kCal, Vitamin D
content 12 IU/oz) and cholecalciferol was given at a
daily dose of 400 IU daily to suppress PTH [8]. In sum,
her total daily vitamin D intake was approximately
600 IU.
Follow up course
Over the next 18 months, she continued on cholecalci-
ferol and a regular age-appropriate diet. Her length and
weight decreased from the 75th percentile at birth to the
25-50th percentile by 6 months of age but then pro-
gressed consistently at the 50th percentile for length and
the 25th percentile for weight. The iPTH fell steadily
from its peak of 20.4 pmol/L to 4.0 pmol/L by 2 months
of age and then settled in the high normal range just
under 6 pmol/L. At 12 months of age, the iPTH
Table 1 Initial biochemical parameters of the infant and mother
Lab results Initial Lab Results
Infant, 2 wks Infant’s mother
Ca {2.3-2.8 mmol/L}; (2.2-2.5 mmol/L) 3.08 2.33
Phos {1.45-2.16 mmol/L}; (0.87-1.45 mmol/L) 1.87 1.42
Mg (0.65-1.0 mmol/L) 1.05
Cr {25.0-75.0 mol/L}; (41.6-83.3) 25.0 58.3
Alkaline Phosphatase {150–420 U/L}; (30–120 U/L) 364
Calcium creatinine clearance ratio* 0.0004 0.0005
iPTH (1.0-6.5 pmol/L) 20.4 5.7
Vit D 25(OH) (80–250 nmol/L) 45.18
Vit D 1,25(OH)2 (42–169 pmol/L) 421.2
Normal adult ranges are given in parenthesis. Normal ranges for infants up to 24 months are given in curly brackets where applicable.
*CCCR – calcium creatinine clearance ratio =U-calcium/S-calcium/U-creatinine/S-creatinine; calculated with spot urine and serum indices. CCCR <0.02 considered
hypocalciuric [9].
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dose was increased to 800 IU/day. Calcium levels
remained between 3.1 and 3.3 mmol/L with low cal-
cium/creatinine clearance ratios (Figure 2). Follow-up
films of the chest and femurs at age 3 months and again
at 1 year showed resolution of metaphyseal deformities
and periosteal reaction with improving femoral bowing
deformities (Figure 3). Renal ultrasound performed at
1 year was normal without evidence of nephrocalcinosis.
At her final appointment before being lost to follow-up
at age 19 months, her iPTH was 6.6 pmol/L.Genetic evaluation
A CaSR gene mutation study (GeneDx DNA diagnostic
experts, Gaithersburg, MD) demonstrated heterozygosity
for a T>C nucleotide substitution at c.1664 in exon 6,
resulting in an amino acid change I555T in the extracel-
lular domain, which replaces an isoleucine with a threo-
nine. This amino acid substitution was predicted by
computer modeling performed by GeneDx to be a be-
nign sequence variant although it occurs at a highly con-
served region in the CaSR gene [5,10]. The mother’s
CaSR mutation testing was normal and the father is
unknown.Discussion
The severity of the clinical picture in this case including
intrauterine fractures was unusual. Classical FHH due to
a heterozygous loss of function (LOF) mutation of the
CaSR can go unrecognized for years and only rarely is
diagnosed in the neonatal period. However, heterozygous
forms of FHH with overt neonatal bone disease are
described in the literature and are typically defined as
NHPT [5-7,10]. Possible causes of the more severe
phenotype seen in these cases include the specific type
of CaSR gene mutation, paternal versus maternalinheritance, prematurity and maternal vitamin D defi-
ciency [4,8].
CaSR mutation type
The exact mechanism of how CaSR activation directs
intracellular signaling leading to inhibition of PTH secre-
tion and increased reabsorption of calcium in kidneys
remains unknown [1]. It is known that the CaSR functions
on the cell surface as a homodimer [11]. Inactivation of
the CaSR gene can be caused by missense, nonsense and
splice –site mutations [10]. The latter two types of muta-
tions lead to truncated CaSR proteins lacking transmem-
brane or intracellular domains. These proteins cannot
dimerize with the wild type CaSR proteins. As a result, in
the heterozygous state, calcium sensing will be limited to
the 50% structurally normal receptors. CaSR proteins
affected by missense mutations can dimerize with the wild
type CaSR protein but lead to a malfunctioning heterodi-
mer. In rare instances, the missense mutations may exert
a dominant negative effect leaving a minority of wild-type
CaSR homodimers functional [4]. Thus, in our case, the
presence of a missense mutation may have contributed to
the more severe clinical picture but functional studies
would be required to further substantiate this possibility.
It is important to note that a point mutation in the same
codon which also led to an I555T missense change was
reported in a patient with FHH and was not present in 94
control patients [10].
Paternal vs. maternal inheritance
Maternal serum calcium, which is actively transported
through the placenta in the third trimester to maintain a
maternal-fetal gradient, impacts fetal calcium metabolism.
An infant with a maternally inherited mutated allele will
have a more benign clinical picture than an infant with a
paternally inherited mutated allele because the resulting










































































Figure 2 Serum Calcium, iPTH, Calcium Creatinine Clearance Ratio (CCCR), alkaline phosphatase levels over the course of observation.
Gray zones indicate the reference ranges for each parameter. CCCR reference range not included due to scale; however, values <0.02 consider
hypocalciuric.
Tonyushkina et al. International Journal of Pediatric Endocrinology 2012, 2012:13 Page 4 of 7
http://www.ijpeonline.com/content/2012/1/13fetal CaSR [8] and inhibit expression PTH secretion. Con-
versely, in an infant with a paternally inherited mutated al-
lele, the normocalcemic maternal environment can lead to
intrauterine fetal hyperparathyroidism as higher calcium
levels would be required to satisfy the mutated fetal CaSR,suppress PTH gene expression, and prevent hyperplasia in
the fetal parathyroid glands. In our case, the missense mu-
tation of the infant was not found in the mother. Therefore,
presumed paternal inheritance or a de novo mutation may
have contributed to the unusually severe presentation.
CBA
Figure 3 Changes in radiographic findings of the left femur over the course of observation (age 2 weeks to 1 year). A. 2 weeks:
antero-lateral bowing, widened and irregular metaphyses with flaring and medial beaking (black arrow), and thick, smooth periosteal reaction
(white arrow). B. 3 months: improved bowing, resolved periosteal reaction and mild residual beaking of the medial upper femoral metaphysis.
C. 1 year: Further improvement in lateral bowing, complete resolution of metaphyseal deformity.
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Prematurity can modify the expected phenotype of
neonatal hyperparathyroidism (NHPT) to one more
similar to NSHPT. Such a case has been reported
previously of an infant born at 27 weeks gestation
with moderate hypercalcemia and severe bone disease
who was found to have an inactivating mutation
(R220W) of CaSR. The infant received serial pamidro-
nate infusions and two parathyroidectomies in an at-
tempt to control the hypercalcemia, but ultimately
succumbed to respiratory disease [12]. Because the
fetal skeleton depends heavily on maternal calcium
and phosphorus transfer during the third trimester,
prematurity predisposes an infant to deficient bone
mineral accrual. An inactivated CaSR in this setting
could lead to further demineralization of an already
weakened skeleton and potentially lead to more se-
vere skeletal findings. In addition, the CaSR is
expressed in the placenta. Mice studies of inactivating
CaSR mutations have found decreased transfer of cal-
cium to the fetus. Theoretically, this could lead to an
additional stimulus for fetal PTH secretion.
Maternal vitamin D deficiency
Maternal vitamin D deficiency with a negative cal-
cium balance has been suggested to cause stimulation
of fetal parathyroid glands in utero [8]. The 25(OH)
D3 in the infant obtained soon after presentation was
within the normal range. The mother’s level at deliv-
ery is unknown but considering the prevalence of
vitamin D deficiency in New England [13] and thefact that this child was born in March, it is plausible
that some degree of maternal D insufficiency was
involved in the pathogenesis of hyperparathyroidism
in this patient, although likely to a small degree.
After 2–3 months of cholecalciferol treatment, the
skeletal findings resolved and the biochemical para-
meters more closely corresponded to the classical fea-
tures seen in FHH. The infant had a combination of
mild hypercalcemia, mildly elevated serum magnesium,
inappropriately high-normal PTH and low urinary cal-
cium creatinine clearance [1].
Postnatally, the CaSR is not widely expressed in
renal tubular cells but its expression increases over
the first several months leading to enhanced calcium
reabsorption and declining urinary calcium excretion
in the normal infant [14]. In our infant, the calcium/
creatinine clearance ratio (CCCR) was strikingly low
throughout her course and consistently in the range
seen in FHH which is <0.02 [9]. Despite resolution of
the severe hyperparathyroidism over the infant’s first
3 months, her PTH continued to be in the high nor-
mal range despite increasing cholecalciferol dosing.
This might indicate a more severe than average
course, since persistent elevation of PTH is reported
only in 20% of cases of FHH [10]. In addition, CaSR
mutations are associated with adenomatous primary
hyperparathyroidism [15].
We elected to use cholecalciferol to try to hasten the
resolution of the hyperparathyroidism because of the ac-
tive bone disease. Within the parathyroid glands, local
conversion of 25(OH)D3 to 1,25(OH)2 D3 has been
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and PTH production [16]. 1,25(OH)2 D3 is known to
regulate PTH and CaSR gene expression as well as para-
thyroid cell growth [17]. Vitamin D has been shown to
help decrease PTH levels in primary and secondary
hyperparathyroidism [18] and has been used in the treat-
ment of clinically significant FHH [8]. Our experience
showed that cholecalciferol treatment was safe. Poten-
tially it may have supported the infant in achieving the
elevated threshold for calcium-sensing of the mutated
CaSR, but its role in moderating symptomatic FHH or
altering the natural course of FHH has to be further
investigated. Another medical treatment option for cases
such as this would be calcimemetics like cinacalcet. This
agent activates the CaSR through binding to the seven
transmembrane domain of the CaSR and has been
shown to improve the sensitivity of the parathyroid
glands to calcium and to treat hyperparathyroidism [19].
Since there is significant genetic heterogeneity in FHH,
calcimemetics might not render equivalent effects in dif-
ferent types of CaSR mutations. One might consider using
a calcimemetic in the future if the persistent hyperparathyr-
oidism and hypercalcemia leads to complications.Conclusion
In summary, this report describes a case of neonatal
FHH secondary to a heterozygous inactivating missense
mutation within the CaSR gene that presented with se-
vere hyperparathyroidism, overt neonatal skeletal
demineralization and perinatal fractures. We reviewed
the possible causes of the uncommonly severe clinical
picture and its resolution. And finally, we discussed the
theoretical role of cholecalciferol in supporting the in-
fant with clinically significant neonatal FHH via PTH
suppression. This child will require careful follow-up as
her PTH level still remains elevated placing her at risk
of clinical hyperparathyroidism in the future as well as
monitoring for the development of primary HPT which
has been reported in cases of FHH.Consent
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for publication of this case and any accompanying
images.
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